spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PCI Announces Expansion of High Potent Tableting and Powder Modification Capacity

PCI Pharma Services

Investment in new technologies at PCIs global manufacturing Center of Excellence in Tredegar Wales to double highly potent tableting capacity and boost powder handling capability

Philadelphia, USA – March 25, 2019 PCI Pharma Services (PCI), full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global biopharmaceutical industry, has announced further investment to expand its flagship manufacturing center in Tredegar, Wales.

PCI’s investment at Tredegar will double its highly potent tableting capacity and see an increase in general throughput to support recent and anticipated product launches. It is the latest investment at PCI’s core manufacturing site within its global network, made in direct response to customer needs and market growth.

PCI’s Richard Yarwood, Senior Vice President, said: “We are delighted to announce these most recent investments as part of both our business continuity and growth strategies. This additional capacity will provide greater security to our customers, supporting important clinical programs and new product or market launches.”

Since opening its dedicated contained manufacturing facility in 2013, PCI Tredegar has processed more than 60 highly potent products within the unit. The purpose-built, state-of-the-art facility enables PCI to offer a market-leading service; with design for manufacture principles and geometric scale-up delivering seamless development to commercial launch services and speed to market for PCI’s international customer base.

Additional investments made at PCI Tredegar since 2013 have further enhanced the facility, complementing the initial build. These include fully contained roller compaction for the processing of molecules sensitive to heat and/or moisture, as well as contained Xcelodose® technology delivering drug in capsule solutions for early stage clinical development programs, delivering cost and time efficiencies for customers. In addition to these solid oral dose processing capabilities, further investments in technologies to support the processing of highly potent liquids and semi-solids complete PCI’s full service offering for multiple dosage forms.

Such strategic investment in cutting-edge technology and processes, bolstered by lean techniques and safety innovations, has continued. Most recently, in 2018, PCI extended the capacity of its analytical laboratory in support of growth in the potent market. The laboratory project increased analytical capacity to support development and commercial raw material, in-process and finished product testing. The layout design incorporated lean philosophies and optimized safety with the installation of specific, high potent drug containment enclosures.

Commenting on these investments, Richard said: “We have developed the PCI Tredegar site in direct response to growing customer demand for the development and commercial supply of potent drug products. We are proud to be a trusted partner to more than half of the top 20 pharmaceutical companies globally and our investments have been carefully considered to ensure we keep pace with customer needs, today and in the future.”

He continued: “PCI has built significant experience in the effective processing of these often challenging highly potent molecules. Our customers value us for our ongoing investment in leading-edge technology, combined with the commitment of our highly skilled scientists and trained.”

To find out more about PCI, please visit here.

About PCI Pharma Services
The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

Contact

Carrie Lowe at BECG / Tom Gosschalk /

T: +44 (0)1962 893 913 / +44 (0)20 3697 7647
phone +44 (0)1495 713 633
email sales@pciservices.com
web www.pciservices.com
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Validation batches of the vaccine against equine strangles Strangvac® is completed

[Noáin, January 27, 2020] 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics has, together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against equine strangles called Strangvac®. The validation production batches required for the forthcoming registration application to the European Medicines Agency, EMA, are thus finalized.
More info >>


White Papers

High-tech Packaging for High-tech Medicine

West Pharmaceutical Services, Inc.

As more biologics and biosimilars come on to the global pharmaceutical market, they can and will present unique packaging and containment challenges. For materials that are sensitive to glass or that may require larger-dose volumes or custom configurations, cyclic olefin polymers may offer a solution. These novel materials for drug container closure systems can provide a needed alternative to traditional glass containment systems for advanced therapeutics.
More info >>

Industry Events

Evolution Summit

4-7 May 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement